Company file · RVTY

Revvity

Revvity's revenue rose 3.7% in FY2025, to $2.9B, and net income fell 10.8% to $241M

Revenue rose 3.7% to $2.9B in FY2025, from $2.8B in FY2024. Net income fell 10.8% to $241M. Life Sciences was the largest segment, at 50% of revenue.

Prepared from SEC filings · Latest annual report: 10-K for FY2025 (filed Feb 24, 2026) · Latest quarter: 10-Q for the quarter ended Oct 4, 2026 (filed Nov 10, 2026) · Data pulled Nov 11, 2026

Key facts

Revvity (NYSE: RVTY) closed fiscal 2025 on Dec 28, 2025 with revenue of $2.9B, up 3.7% from a year before; net income came to $241M, down 10.8%. Its newest quarterly report covers the three months to Oct 4, 2026: revenue of $729M, up 4.3% on the same stretch of the prior year, and net income of $62M. Broken down by segment, Life Sciences led with 50% of fiscal 2025 revenue. Sources: 10-K for fiscal 2025 (filed Feb 24, 2026) and 10-Q for the quarter ended Oct 4, 2026 (filed Nov 10, 2026).

Revenue$2.9BFY2025 · +3.7% vs FY2024

Net income$241MFY2025 · −10.8% vs FY2024

Operating cash flow$583MFY2025 · −7.2% vs FY2024

Cash & equivalents$593Mat Oct 4, 2026 · −35.6% vs FY2025 end

Total debt$3.2BFY2025 end · +2.1% vs FY2024

Diluted shares117MFY2025 avg · −5.1% vs FY2024

Revenue and net income, three fiscal yearsBy fiscal year, $bn

RevenueNet income

Source: 10-K FY2025, filed Feb 24, 2026

Quarterly revenue: fiscal 2026 vs a year earlierFiscal Q1–Q3, $bn (each quarter from that quarter's 10-Q)

FY2025FY2026

Source: 10-Q filed May 12, 2026 · 10-Q filed Aug 11, 2026 · 10-Q filed Nov 10, 2026

How it makes money

By segment, FY2025

LineAmountSharevs FY2024
Life Sciences$1.4B50%+2.3%
Diagnostics$1.4B50%+5.1%

Source: 10-K FY2025, XBRL breakdown

By segment in FY2025: Life Sciences (50%) and Diagnostics (50%), as shares of total revenue. Total revenue was $2.9B.

By segment: three-year mixShare of the total each fiscal year

FY2023

53%47%

FY2024

51%49%

FY2025

50%50%

Life SciencesDiagnostics

Source: 10-K FY2025

By product or service, FY2025

Products$2.4B84%+2.2%

Services$466M16%+11.8%

Share is of the FY2025 total; the last column is the change from FY2024.

Learn more: Revenue vs. net income · Gross, operating and net margin

What changed last quarter

How the quarter compared with a year earlier

Comparing Q3 FY2026 (Jul to Sep 2026) compared with Q3 FY2025 (Jul to Sep 2025)

Each pair of bars shows the dollar amount for both quarters. Longer bar, more money. Bars in a group share one scale.

Q3 FY2026Q3 FY2025

Company

Revenue

$729M Q3 FY2026

$699M Q3 FY2025

4.3% increase

Net income

$62M Q3 FY2026

$47M Q3 FY2025

33.5% increase

Source: Revvity 10-Q for the quarter ended Oct 4, 2026, filed Nov 10, 2026

By segment

Life Sciences

$380M Q3 FY2026

$343M Q3 FY2025

10.7% increase

Diagnostics

$349M Q3 FY2026

$356M Q3 FY2025

1.9% decrease

Source: Revvity 10-Q for the quarter ended Oct 4, 2026, filed Nov 10, 2026

Cash & equivalents $593M at Oct 4, 2026, vs $920M at FY2025 end.
Operating cash flow, first 9 months of fiscal 2026: $474M vs $401M a year earlier.

The bull case and the bear case

The bull case

Revenue rose 3.7% in FY2025 to $2.9B, from $2.8B a year earlier. 10-K, FY2025
Diluted shares fell 5.1% in FY2025, so each share represents a larger slice of profit. 10-K, FY2025
Revenue in the quarter ended Oct 4, 2026 was $729M, up 4.3% on a year earlier. 10-Q, quarter ended Oct 4, 2026
Diagnostics revenue grew 5.1% in FY2025 to $1.4B. 10-K, FY2025
Net income in the quarter ended Oct 4, 2026 was $62M, up 33.5% on a year earlier. 10-Q, quarter ended Oct 4, 2026

The bear case

Net income fell 10.8% in FY2025 to $241M, from $270M. 10-K, FY2025
Operating cash flow fell 7.2% in FY2025 to $583M. 10-K, FY2025

What optimists and skeptics tend to point to, each tied to a filing. Ticker Sage doesn't pick a side, and neither list is a reason to buy or sell.

What the company does

Revvity is in the health care equipment industry, part of the health care sector. The SEC files it under Laboratory Analytical Instruments.

Revvity reports 2 segments: Life Sciences and Diagnostics.

Its fiscal year ends in December; the latest, FY2025, ended Dec 28, 2025.

Source: 10-K, Item 1 Business

Risks common in this industry

These are general risks for companies in the health care equipment industry. They are not a summary of Revvity’s own risk factors; for those, read Item 1A of its latest 10-K, linked below.

RegulationApprovals, safety rules and government oversight shape what it can sell and how.
Pricing and reimbursementPayers, insurers and governments influence what it can charge.
CompetitionNew treatments, generics and rival products can take share.
LitigationProduct liability and other legal claims can lead to costs.
SupplyManufacturing and supplier problems can interrupt products.

Source: 10-K, Item 1A Risk Factors (the company's own list, in the company's words)

Three years of key numbers

Every number links to its filing; hover for the XBRL tag. A dash means the number isn't cleanly available, and we don't estimate it.

US$	FY2023	FY2024	FY2025
Revenue	$2.8B	$2.8B	$2.9B
Net income	$693M	$270M	$241M
Operating cash flow	$91M	$628M	$583M
Cash & equivalents (year end)	$913M	$1.2B	$920M
Total debt (year end)	$3.9B	$3.2B	$3.2B
Diluted shares	125M	123M	117M

Revenue: Total revenue for the fiscal year, as the company reports it on its income statement.
Net income: Net income attributable to the company's shareholders, after all costs, interest and taxes.
Operating cash flow: Cash the business brought in from its day-to-day operations during the year (cash flow statement).
Cash & equivalents: Cash and short-term investments that count as cash equivalents on the balance sheet. Excludes longer-dated marketable securities.
Total debt: Short-term and long-term debt combined, at carrying value, as the company totals it.
Diluted shares: Weighted average shares outstanding for the year, including the effect of options and stock awards.

Learn more: How to read an income statement · Earnings per share, basic and diluted · Free cash flow · How to read a balance sheet · Growth rate calculator · P/E calculator · Market cap calculator · Free cash flow calculator · Return on equity and assets calculator

Explainers for this page

Plain-English guides to terms this file uses, with real numbers from filings.

About these numbers

Recent filings

Form	Filed	Period
10-Q	Nov 10, 2026	Oct 4, 2026
10-Q	Aug 11, 2026	Jul 5, 2026
10-Q	May 12, 2026	Apr 5, 2026
DEF 14A	Mar 16, 2026	Apr 28, 2026
10-K	Feb 24, 2026	Dec 28, 2025

Learn more: 10-K vs. 10-Q vs. 8-K · Form 4 insider filings · Fiscal years and quarters

Common questions about Revvity

How does Revvity make money?

Fiscal 2025 revenue: $2.9B. By segment in FY2025: Life Sciences (50%) and Diagnostics (50%), as shares of total revenue. Total revenue was $2.9B. Source: 10-K for fiscal 2025, filed Feb 24, 2026.

What was Revvity's revenue in fiscal 2025?

$2.9B, up 3.7% from fiscal 2024 ($2.8B). The year ended Dec 28, 2025; for fiscal 2023 the figure was $2.8B. Source: 10-K for fiscal 2025, filed Feb 24, 2026.

Is Revvity profitable?

Net income was $241M in fiscal 2025 (down 10.8%; fiscal 2024 was $270M). That counts as a GAAP profit. The latest quarter, ended Oct 4, 2026: net income was $62M. The page's About these numbers section explains what is included. Source: 10-K for fiscal 2025, filed Feb 24, 2026.

What did Revvity report in its latest quarterly filing?

For the three months to Oct 4, 2026: revenue $729M (up 4.3% from $699M) and net income $62M (up 33.5% from $47M). Source: 10-Q for the quarter ended Oct 4, 2026, filed Nov 10, 2026.

What are the main risks Revvity faces?

Revvity's own risk factors are in Item 1A of its 10-K for fiscal 2025, filed Feb 24, 2026. Risks that are common among companies in the health care equipment industry include Regulation; pricing and reimbursement; competition; litigation; supply. The first: Approvals, safety rules and government oversight shape what it can sell and how. Source: 10-K, Item 1A Risk Factors.

Where do these Revvity numbers come from?

The 10-K filed Feb 24, 2026 (fiscal 2025) and the 10-Q filed Nov 10, 2026 (quarter ended Oct 4, 2026), as published in the SEC's XBRL data. Click any number to open the filing it came from. Methodology explains how fiscal years and missing numbers are handled.

Tracked funds that report owning Revvity

Citadel Advisors: 1,457,335 shares, reported value $162.1M at Jun 30, 2026 (+2,226.0% in shares since the filing for Mar 31, 2026). Form 13F filed Sep 2, 2026.
Millennium Management: 75,229 shares, reported value $8.4M at Jun 30, 2026 (new in this filing). Form 13F filed Aug 14, 2026.
Bridgewater Associates: 24,161 shares, reported value $2.7M at Jun 30, 2026 (−34.8% in shares since the filing for Mar 31, 2026). Form 13F filed Aug 14, 2026.
Two Sigma Investments: 11,386 shares, reported value $1.3M at Jun 30, 2026 (new in this filing). Form 13F filed Aug 14, 2026.

From each fund’s latest Form 13F, which is filed up to 45 days after quarter end and lists long positions in US-listed stocks only. A listing here is a fact about a filing, not a view on the stock. What a 13F does and doesn’t show.

Disclosures

Editor holdings in RVTY: The editor holds no position in Revvity (RVTY). As of Nov 11, 2026.
Trading rule: The editor does not buy or sell RVTY from 3 days before to 3 days after this page is published or substantively updated.
Compensation: Nobody paid for this page. No affiliate links on this page.
Sources: The company's SEC filings, linked next to each number or, for charts, in the source line under them.
Last updated: Nov 11, 2026

General education, the same for every reader. Not a recommendation to buy, sell or hold RVTY, and it doesn't consider your situation.

Compare with peers

Company	Fiscal year	Revenue	Revenue growth	Net income
RevvityRVTY	FY2025	$2.9B	+3.7%	$241M
AbbottABT	FY2025	$44.3B	+5.7%	$6.5B
Intuitive SurgicalISRG	FY2025	$10.1B	+20.5%	$2.9B
MedtronicMDT	FY2026	$36.4B	+8.4%	$4.8B
StrykerSYK	FY2025	$25.1B	+11.2%	$3.2B

Each row is that company’s latest fiscal year from its own 10-K, using its own revenue and net income lines. Fiscal years end in different months, and line definitions differ (banks, insurers and oil companies count revenue differently), so this is a rough side-by-side, not a like-for-like comparison.

More company files

New to filings? Learn has plain-English explainers and Tools has calculators. Methodology & Disclosures covers where every number comes from.